华熙生物科技股份有限公司 2025年第一次临时股东会会议资料 证券代码：688363 证券简称：华熙生物 华熙生物科技股份有限公司 2025年第一次临时股东会会议资料 华熙生物科技股份有限公司 2025 年第一次临时股东会会议资料 2025 年 10 月 华熙生物科技股份有限公司 2025年第一次临时股东会会议资料 2025 年第一次临时股东会会议资料目录 | 华熙生物科技股份有限公司 | | 2025 | 年第一次临时股东会会议须知 | 1 | | --- | --- | --- | --- | --- | | 华熙生物科技股份有限公司 | | 2025 | 年第一次临时股东会会议议程 | 4 | | 议案一 2025 | 关于续聘公司 | 年度审计机构的议案 | | 6 | | 华熙生物科技股份有限公司拟聘任会计师事务所的基本情况 | | | | 7 | 2025 年第一次临时股东会会议须知 为保障华熙生物科技股份有限公司（以下简称"公司"）全体股东的合法权 益，维护股东会的正常秩序，保证股东会的议事效率，确保本次股东会如期、顺 利召开，根据《中华人民共和国公司法》《华熙生物科技股份有限公司章程》《华 熙 ...

Market Overview - The medical beauty sector experienced a decline of 0.5% on October 10, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - The following stocks in the medical beauty sector showed varying performance: - *ST Meigu (000615)*: Closed at 3.30, down 0.30% with a trading volume of 64,200 shares [1] - Aimeike (300896): Closed at 179.84, down 0.32% with a trading volume of 27,000 shares [1] - Huaxi Biological (688363): Closed at 55.78, down 0.76% with a trading volume of 38,500 shares [1] - Jinbo Biological (920982): Closed at 267.48, down 1.95% with a trading volume of 9,733 shares [1] Capital Flow - The medical beauty sector saw a net inflow of 14.16 million yuan from main funds, while retail funds experienced a net outflow of 8.85 million yuan [1] - Detailed capital flow for specific stocks includes: - Aimeike (300896): Net outflow of 11.73 million yuan, down 2.40% [2] - *ST Meigu (000615)*: Net outflow of 1.17 million yuan, down 5.51% [2] - Huaxi Biological (688363): Net outflow of 3.72 million yuan, down 1.72% [2]

Core Insights - The medical beauty sector experienced a slight increase of 0.18% on October 9, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Medical Beauty Sector Performance - Huaxi Biological (688363) closed at 56.21, with a rise of 1.43% and a trading volume of 40,100 shares [1] - Aimeike (300896) closed at 180.42, down 0.62% with a trading volume of 29,300 shares [1] - ST Meigu (000615) closed at 3.31, down 0.90% with a trading volume of 124,000 shares [1] - Jinbo Biological (920982) closed at 272.80, down 3.12% with a trading volume of 10,000 shares [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 44.2015 million yuan from main funds and a net outflow of 32.526 million yuan from speculative funds, while retail investors had a net inflow of 76.7274 million yuan [1] - Huaxi Biological had a main fund net inflow of 5.4613 million yuan, accounting for 2.45% of its total [2] - Aimeike experienced a significant main fund net outflow of 47.1115 million yuan, representing 8.95% of its total [2] - ST Meigu had a main fund net outflow of 2.5512 million yuan, accounting for -6.23% of its total [2]

Investment Rating - The report maintains a "Recommendation" rating for Huaxi Biological [2] Core Views - Huaxi Biological is currently undergoing a systematic adjustment phase, with initial positive results on the profit front. The company reported a revenue of 2.261 billion (down 19.57% year-on-year) and a net profit attributable to the parent company of 221 million (down 35.38%) for the first half of 2025. However, the second quarter showed a turning point with a net profit of 119 million, up 20.89% year-on-year [2][3] - The company is focusing on strategic marketing reductions and effective cost control, leading to a recovery in profitability. The gross margin for the first half of 2025 was 70.99% (down 3.53 percentage points), while the net margin was 9.77% (down 2.39 percentage points) [2][3] - The report highlights the resilience of the sales of Class III medical devices, despite a decline in the skin science innovation transformation business, which saw a revenue drop of 33.97% [2][3] Financial Summary - For 2025, the expected total revenue is 4.959 billion (down 7.7% year-on-year), with a projected net profit of 458 million (up 162.9% year-on-year). The earnings per share are expected to be 0.95 yuan, with a price-to-earnings ratio of 58 [4][9] - The company’s total market capitalization is approximately 26.695 billion, with a current share price of 55.42 yuan and a target price of 64.13 yuan [4][5] - The report anticipates a recovery in the core business operations, with projected net profits for 2025, 2026, and 2027 being 458 million, 618 million, and 748 million respectively [2][4]

Core Points - Huaxi Bio (688363.SH) announced that it received a notification from Huaxi Xinyu regarding share buybacks [1] - From August 27, 2025, to September 30, 2025, Huaxi Xinyu increased its holdings by 4,518,703 shares, accounting for 0.94% of the total share capital [1] - The total amount spent on the share buyback was RMB 257,478,738.40, exceeding the lower limit of the planned buyback amount of RMB 200 million [1] - The buyback plan has been completed [1]

证券代码：688363 证券简称：华熙生物 公告编号：2025-038 华熙生物科技股份有限公司 关于控股股东增持计划实施完毕暨增持股份结果 公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已披露增持计划情况 华熙生物科技股份有限公司（以下简称"公司"）的控股股东华熙昕宇投资 有限公司（以下简称"华熙昕宇"）基于对公司未来发展的信心和长期投资价值 认可，计划自 2025 年 8 月 8 日起的 6 个月内，使用自有资金或自筹资金，通过 上海证券交易所系统允许的方式（包括但不限于集中竞价、大宗交易等）增持公 司股份，增持金额不低于人民币 2 亿元（含），不超过人民币 3 亿元（含），增持 股份比例不超过公司总股本 1%，增持股票价格不超过 70 元/股。具体内容详见 公司于 2025 年 8 月 8 日在上海证券交易所网站（www.sse.com.cn）披露的《华 熙生物科技股份有限公司关于控股股东增持公司股份计划公告》（公告编号： 2025-028）。 增持计划的实施结果 公司于 2025 年 ...

致：华熙生物科技股份有限公司 北京市通商律师事务所(以下简称"本所")是经北京市司法局批准成立，依 法在中华人民共和国(以下简称"中国"，就且仅就本法律意见书而言，不包括 中国香港特别行政区、中国澳门特别行政区和中国台湾地区)从事法律业务的律 师事务所。本所作为华熙生物科技股份有限公司(以下简称"公司")的法律顾问， 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国 证券法》、中国证券监督管理委员会(以下简称"证监会")颁布的《上市公司收 购管理办法》(以下简称"《管理办法》")等有关法律、法规和规范性文件的规 定，按照律师行业公认的业务标准、道德规范和勤勉尽责精神，就公司控股股东 华熙昕宇投资有限公司(以下简称"华熙昕宇"或"控股股东"或"增持人")增 持公司股份(以下简称"本次增持")的相关事项出具本法律意见书。 本所及承办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则(试行)》等规定及本法律意见书出具日以 前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用 原则，进行了充分的核查验证，保证本法律意见所认定的事实真实 ...

Group 1 - The core point of the article is that Huaxi Bio announced a significant share buyback, with Huaxi Xinyu increasing its stake in the company by approximately 4.52 million shares, representing 0.94% of the total share capital, with a total investment of around RMB 257 million, exceeding the lower limit of the planned buyback amount of RMB 200 million [1] Group 2 - The share buyback took place between August 27, 2025, and September 30, 2025, through the Shanghai Stock Exchange trading system via centralized bidding [1] - The buyback plan has been completed successfully, indicating strong confidence from Huaxi Xinyu in Huaxi Bio's future performance [1]

证券代码：688363 证券简称：华熙生物 公告编号：2025-037 华熙生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、 拟聘任会计师事务所的基本情况 （一） 机构信息 1. 基本信息 | 名称 | 致同会计师事务所（特殊普通合伙），前身是 1981 年成立的北 | | | | | --- | --- | --- | --- | --- | | | 京会计师事务所，2011 年经北京市财政局批准转制为特殊普 | | | | | | 通合伙，2012 年更名为致同会计师事务所(特殊普通合伙) | | | | | 成立日期 1981 | 年 特殊普通合伙企业 | 组织形式 | | | | 注册地址 | 北京市朝阳区建国门外大街 | 22 | 号赛特广场 | 5 层 | | 首席合伙人 李惠琦 | 239 人 | 上年度末合 | | | | | | 伙人数量 | | | | 上年末执业人员 | 注册会计师人数 | 1359 人 | | | | 数量 | 签署过证券服务业 | 445 ...

Core Viewpoint - The controlling shareholder of Huaxi Biological, Huaxi Xinyu Investment Co., Ltd., has completed a share buyback plan, increasing its stake in the company significantly [1] Summary by Relevant Sections - **Share Buyback Details** - From August 27, 2025, to September 30, 2025, Huaxi Xinyu Investment Co., Ltd. acquired a total of 4.5187 million shares through centralized bidding on the Shanghai Stock Exchange, representing 0.94% of the company's total share capital [1] - The total amount spent on the buyback was 257 million yuan [1] - **Shareholding Changes** - Prior to the buyback, Huaxi Xinyu held 283 million shares, accounting for 58.86% of the total shares [1] - After the buyback, the total shares held increased to 290 million, raising the ownership percentage to 60.11% [1] - **Completion of Buyback Plan** - The share buyback plan has been fully implemented as of the announcement date [1]